XOMA Reports Fourth Quarter and Full-Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches up on megacap strength; Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar rises to session high after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
- Ovintiv adds 41,000 acres in Permian and Montney deals
RBC Capita Affirms XOMA (XOMA) at 'Sector Perform'; Gevokizumab Sale Could Bring in More non-Dilutive Cash
March 10, 2016 7:41 AM ESTRBC Capita affirms XOMA Corporation (Nasdaq: XOMA) with a Sector Perform rating and $2 price target following Q4 results and update issued Wednesday night:
Analyst Adnan Butt commented: Focus now is earlier stage endocrine programs with enough cash at hand through proof of... More
XOMA (XOMA) Tops Q4 Views
March 9, 2016 4:02 PM ESTXOMA (NASDAQ: XOMA) reported Q4 EPS of $0.21, $0.36 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $48.18 million versus the consensus estimate of $4.01 million.
For earnings history and earnings-related data on XOMA (XOMA) click here.
... More